Protagonist Therapeutics, Inc. (PTGX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 03:45PM EDT. Market open.
| Previous close | 29.61 |
| Open | 30.00 |
| Bid | 31.30 x 100 |
| Ask | 31.43 x 300 |
| Day's range | 29.93 - 32.25 |
| 52-week range | 13.72 - 33.34 |
| Volume | |
| Avg. volume | 557,585 |
| Market cap | 1.839B |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | 12.35 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Turnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
© 2024 Yahoo. All rights reserved.